Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P30279

UPID:
CCND2_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P30279; A8K531; Q13955; Q5U035

BACKGROUND:
The regulatory component of the cyclin D2-CDK4 complex, G1/S-specific cyclin-D2, is essential for the phosphorylation of retinoblastoma proteins, enabling the cell to progress from the G1 to the S phase. This process is crucial for cell proliferation and growth, with cyclin D2-CDK4 complexes serving as key mediators of cellular responses to growth signals.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of G1/S-specific cyclin-D2 could open doors to potential therapeutic strategies. Its involvement in Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3 highlights its potential as a target for therapeutic intervention in diseases caused by dysregulated cell cycle progression.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.